ATE211762T1 - Antisense-oligonukleotide zur behandlung des immunsuppressiven effektes des transformierenden wachstumsfaktor-beta1(tgf-beta1) - Google Patents

Antisense-oligonukleotide zur behandlung des immunsuppressiven effektes des transformierenden wachstumsfaktor-beta1(tgf-beta1)

Info

Publication number: ATE211762T1
Authority: AT; Austria
Prior art keywords: beta1; tgf; growth factor; transforming growth; treating
Prior art date: 1993-04-30

Application number

AT94916170T

Other languages

English (en)

Inventor

Georg-Ferdinan Schlingensiepen

Wolfgang Brysch

Karl-Hermann Schlingensiepen

Reimar Schlingensiepen

Ulrich Bogdahn

Original Assignee

Biognostik Ges

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-04-30

Filing date

1994-04-29

Publication date

2002-01-15

1994-04-29 Application filed by Biognostik Ges filed Critical Biognostik Ges

2002-01-15 Application granted granted Critical

2002-01-15 Publication of ATE211762T1 publication Critical patent/ATE211762T1/de

Links

108020000948 Antisense Oligonucleotides Proteins 0.000 title abstract 2
239000000074 antisense oligonucleotide Substances 0.000 title abstract 2
238000012230 antisense oligonucleotides Methods 0.000 title abstract 2
102000046299 Transforming Growth Factor beta1 Human genes 0.000 title 1
101800002279 Transforming growth factor beta-1 Proteins 0.000 title 1
230000001506 immunosuppresive effect Effects 0.000 title 1
229940099456 transforming growth factor beta 1 Drugs 0.000 title 1
150000007523 nucleic acids Chemical group 0.000 abstract 3
102000004887 Transforming Growth Factor beta Human genes 0.000 abstract 2
108090001012 Transforming Growth Factor beta Proteins 0.000 abstract 2
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract 2
108020004707 nucleic acids Proteins 0.000 abstract 1
102000039446 nucleic acids Human genes 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Wood Science & Technology (AREA)
Molecular Biology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Zoology (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Endocrinology (AREA)
Biochemistry (AREA)
Diabetes (AREA)
Hematology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)

AT94916170T 1993-04-30 1994-04-29 Antisense-oligonukleotide zur behandlung des immunsuppressiven effektes des transformierenden wachstumsfaktor-beta1(tgf-beta1) ATE211762T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP93107089		1993-04-30
EP93107849		1993-05-13
PCT/EP1994/001362 WO1994025588A2 (en)	1993-04-30	1994-04-29	ANTISENSE-OLIGONUCLEOTIDES FOR THE TREATMENT OF IMMUNOSUPPRESSIVE EFFECTS OF TRANSFORMING GROWTH FACTOR-β (TGF-β)

Publications (1)

Publication Number	Publication Date
ATE211762T1 true ATE211762T1 (de)	2002-01-15

Family

ID=26133181

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT94916170T ATE211762T1 (de)	1993-04-30	1994-04-29	Antisense-oligonukleotide zur behandlung des immunsuppressiven effektes des transformierenden wachstumsfaktor-beta1(tgf-beta1)
AT99125278T ATE235549T1 (de)	1993-04-30	1994-04-29	Antisense oligonukleotide zur behandlung von immunsuppressiven wirkungen von tgf-beta2

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
AT99125278T ATE235549T1 (de)	1993-04-30	1994-04-29	Antisense oligonukleotide zur behandlung von immunsuppressiven wirkungen von tgf-beta2

Country Status (6)

Country	Link
US (3)	US6455689B1 (de)
JP (2)	JP3555952B2 (de)
AT (2)	ATE211762T1 (de)
AU (1)	AU6794594A (de)
DE (2)	DE69429617T2 (de)
WO (1)	WO1994025588A2 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6395494B1 (en)	1993-05-13	2002-05-28	Neorx Corporation	Method to determine TGF-β
US6884787B2 (en)	2001-07-14	2005-04-26	Isis Pharmaceuticals, Inc.	Antisense modulation of transforming growth factor-beta 3 expression
US5772995A (en) *	1994-07-18	1998-06-30	Sidney Kimmel Cancer Center	Compositions and methods for enhanced tumor cell immunity in vivo
US6207816B1 (en) *	1995-06-02	2001-03-27	Nexstar Pharmaceuticals, Inc.	High affinity oligonucleotide ligands to growth factors
DE19613691A1 (de) *	1996-04-05	1997-10-09	Boehringer Ingelheim Int	Arzneimittel für die Behandlung von Tumorerkrankungen
EP0856579A1 (de)	1997-01-31	1998-08-05	BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH	Ein Verfahren zur Zubereitung von Antisense Oligonukleotiden
WO1998046588A2 (en)	1997-04-11	1998-10-22	Neorx Corporation	Compounds and therapies for the prevention of vascular and non-vascular pathologies
CA2334960C (en)	1998-06-10	2012-01-03	Biognostik Gesellschaft Fur Biomolekulare Diagnostik Mbh	Combination of tgf-.beta. inhibition and immune stimulation to treat hyperproliferative diseases
FR2790955B1 (fr)	1999-03-19	2003-01-17	Assist Publ Hopitaux De Paris	Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
US6436909B1 (en) *	1999-09-17	2002-08-20	Isis Pharmaceuticals, Inc.	Antisense inhibition of transforming growth factor-β expression
EP1133988A1 (de)	2000-03-11	2001-09-19	Biognostik Gesellschaft für biomolekulare Diagnostik mbH	Mischung enthaldend einen Inhibitor oder Suppressor von einen Gens und eine Moleküle bindende des Expressionprodukt des Gens
US7101543B2 (en)	2000-03-31	2006-09-05	Novarx	Genetically modified cells expressing a TGFβ inhibitor, the cells being lung cancer cells
US6613083B2 (en)	2001-05-02	2003-09-02	Eckhard Alt	Stent device and method
PT1456380E (pt) *	2001-11-02	2012-07-23	Giuliani Int Ltd	Inibidores smad7 para o tratamento de doenças do snc
KR20030056538A (ko) *	2001-12-28	2003-07-04	주식회사 웰진	리본형 안티센스 올리고뉴클레오티드에 의한 형질전이성장 인자-β1의 효과적 저해제 개발
CA2388049A1 (en)	2002-05-30	2003-11-30	Immunotech S.A.	Immunostimulatory oligonucleotides and uses thereof
US20050090433A1 (en) *	2002-11-18	2005-04-28	Vicuron Pharmaceuticals, Inc	Dalbavancin compositions for treatment of bacterial infections
CN1756773A (zh) *	2003-03-03	2006-04-05	斯蒂潘公司	降低天然橡胶胶乳制品的变应原性蛋白质含量的方法
ITRM20030149A1 (it)	2003-04-02	2004-10-03	Giuliani Spa	Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
US7399853B2 (en)	2003-04-28	2008-07-15	Isis Pharmaceuticals	Modulation of glucagon receptor expression
US7750142B2 (en) *	2003-04-28	2010-07-06	Isis Pharmaceuticals, Inc.	Modulation of glucagon receptor expression
ATE466595T1 (de) *	2003-07-16	2010-05-15	Rvx Therapeutics Inc	Verbindungen und methoden für das downregulating der effekte von tgf-beta
ES2594734T3 (es) *	2003-12-19	2016-12-22	Autotelic Llc	Terapia de combinación que asocia un antagonista de TGF-beta con un agente quimioterapéutico
EP2248895B8 (de)	2003-12-19	2016-09-21	Autotelic LLC	Kombinations-therapie die ein TGF-beta Antagonisten mit einem Chemotherapeutikum assoziiert
EP1708712A1 (de) *	2003-12-24	2006-10-11	Scios, Inc.	Behandlung von malignen gliomen mit tgf-beta-hemmern
AU2005218759B2 (en) *	2004-02-27	2009-07-16	Antisense Pharma Gmbh	Pharmaceutical composition
EP1568383A3 (de) *	2004-02-27	2005-11-16	Antisense Pharma GmbH	Verwendung eines Oligonukleotide oder seiner aktiven Ableitung für die Zubereitung einer pharmazeutische Zusammensetzung zur Hemmung der Metastasenbildung in Krebsbehandlung
RU2386638C2 (ru)	2004-03-31	2010-04-20	Дженентек, Инк.	Гуманизированные анти-тфр-бета-антитела
DE102004025881A1 (de) *	2004-05-19	2006-01-05	Beiersdorf Ag	Oligoribonukleotide zur Beeinflussung des Haarwachstums
NZ562954A (en) *	2005-05-05	2009-10-30	Antisense Pharma Gmbh	Use of low doses of oligonucleotides antisense to TGF-beta, VEGF, interleukin-10, C-JUN, C-FOS or prostaglandin E2 genes in the treatment of tumors
ES2369328T3 (es) *	2005-09-19	2011-11-29	Isis Pharmaceuticals, Inc.	Modulación de la expresión del receptor de glucagón.
WO2007050793A2 (en)	2005-10-25	2007-05-03	The Johns Hopkins University	Methods and compositions for the treatment of marfan syndrome and associated disorders
EP1998810A4 (de)	2006-03-13	2009-09-02	Univ Johns Hopkins	Erhöhung der endothelialen thromboresistenz
PL2918288T3 (pl)	2006-10-03	2018-02-28	Genzyme Corporation	Zastosowanie antagonistów TGF beta do leczenia niemowląt obarczonych ryzykiem rozwinięcia dysplazji oskrzelowo-płucnej
US8822425B2 (en) *	2008-11-14	2014-09-02	Antisense Pharma Gmbh	Dosage of oligonucleotides suitable for the treatment of tumors
EP2524038A4 (de) *	2010-01-12	2013-11-20	Isis Pharmaceuticals Inc	Modulation der transformierung einer wachstumsfaktor-beta-1-expression
US8911736B2 (en)	2010-03-12	2014-12-16	Genzyme Corporation	Combination therapy for treating breast cancer
WO2011154542A1 (en)	2010-06-11	2011-12-15	Artisense Pharma Gmbh	Method for selective oligonucleotide modification
KR20130131414A (ko)	2010-12-27	2013-12-03	엘에스아이피 환도 운에이고우도우가이샤	ｉＰＳ 세포와 그 제조법
WO2013014262A1 (en)	2011-07-27	2013-01-31	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for diagnosing and treating myhre syndrome
CA2849273C (en)	2011-09-20	2020-07-21	Isis Pharmaceuticals, Inc.	Antisense modulation of gcgr expression
CA2853484C (en)	2011-10-26	2018-08-21	Seattle Children's Research Institute	Cysteamine in the treatment of fibrotic disease
ES2917222T3 (es)	2011-12-28	2022-07-07	Kyoto Prefectural Public Univ Corp	Normalización del cultivo de células endoteliales de la córnea
KR102338833B1 (ko)	2012-02-06	2021-12-13	인히브릭스, 인크.	Cd47 항체 및 그 사용 방법
BR112015024729B1 (pt)	2013-03-27	2022-02-15	Isarna Therapeutics Gmbh	Oligonucleotídeo antissenso, seu uso e composição farmacêutica
JP6492053B2 (ja)	2013-03-27	2019-03-27	イサルナセラピューティクスゲゼルシャフトミットベシュレンクテルハフツング	修飾ｔｇｆ−ベータオリゴヌクレオチド
DK2978846T3 (da)	2013-03-27	2020-04-06	Isarna Therapeutics Gmbh	Modificeret tgf-beta-oligonukleotid til anvendelse i en fremgangsmåde til forebyggelse og/eller behandling af en oftalmisk sygdom
CA2927898C (en)	2013-10-31	2021-11-16	Kyoto Prefectural Public University Corporation	Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium
WO2016187312A1 (en)	2015-05-18	2016-11-24	The Arizona Board Of Regents On Behalf Of The University Of Arizona	Methods and compositions for treating an alphavirus infection
US9758786B2 (en)	2016-02-09	2017-09-12	Autotelic, Llc	Compositions and methods for treating pancreatic cancer
KR20180103816A (ko)	2016-02-09	2018-09-19	오토텔릭 엘엘씨	췌장암을 치료하기 위한 조성물과 방법
KR20220039639A (ko)	2020-09-21	2022-03-29	오토텔릭바이오 주식회사	안티센스 올리고뉴클레오타이드
AU2024284737A1 (en) *	2023-06-05	2026-01-22	Gmp Biotechnology Limited	Tgfb2-irf5 therapeutics for cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0293785A3 (de) *	1987-05-29	1990-05-02	Oncogen Limited Partnership	Klonierung und Expression von transformierendem Affenwachstumsfaktor-SS 1
US5221620A (en) *	1987-10-06	1993-06-22	Oncogen	Cloning and expression of transforming growth factor β2
GB8927546D0 (en) *	1989-12-06	1990-02-07	Ciba Geigy	Process for the production of biologically active tgf-beta
US5525468A (en) *	1992-05-14	1996-06-11	Ribozyme Pharmaceuticals, Inc.	Assay for Ribozyme target site
US5596072A (en) *	1992-08-21	1997-01-21	Schering Corporation	Method of refolding human IL-13
US5464945A (en) *	1992-08-28	1995-11-07	Hoffmann-La Roche Inc.	Oligonucleotide probes specific for the human alpha satellite locus

1994
- 1994-04-29 AT AT94916170T patent/ATE211762T1/de active
- 1994-04-29 DE DE69429617T patent/DE69429617T2/de not_active Expired - Lifetime
- 1994-04-29 AU AU67945/94A patent/AU6794594A/en not_active Abandoned
- 1994-04-29 DE DE69432375T patent/DE69432375T2/de not_active Expired - Lifetime
- 1994-04-29 JP JP52389894A patent/JP3555952B2/ja not_active Expired - Lifetime
- 1994-04-29 WO PCT/EP1994/001362 patent/WO1994025588A2/en not_active Ceased
- 1994-04-29 AT AT99125278T patent/ATE235549T1/de active
- 1994-04-29 US US08/535,249 patent/US6455689B1/en not_active Expired - Lifetime
2002
- 2002-05-16 US US10/146,058 patent/US20030040499A1/en not_active Abandoned
2003
- 2003-06-30 JP JP2003188524A patent/JP3600831B2/ja not_active Expired - Lifetime
2006
- 2006-12-29 US US11/647,586 patent/US7667027B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
JPH08509370A (ja)	1996-10-08
DE69432375T2 (de)	2004-02-12
WO1994025588A2 (en)	1994-11-10
JP3555952B2 (ja)	2004-08-18
DE69429617D1 (de)	2002-02-14
US7667027B2 (en)	2010-02-23
JP2004024264A (ja)	2004-01-29
WO1994025588A3 (en)	1994-12-22
ATE235549T1 (de)	2003-04-15
DE69432375D1 (de)	2003-04-30
AU6794594A (en)	1994-11-21
DE69429617T2 (de)	2002-08-22
US20030040499A1 (en)	2003-02-27
US20080214483A1 (en)	2008-09-04
JP3600831B2 (ja)	2004-12-15
US6455689B1 (en)	2002-09-24

Legal Events

Date	Code	Title	Description
2002-06-15	UEP	Publication of translation of european patent specification

Publication	Publication Date	Title
ATE211762T1 (de)	2002-01-15	Antisense-oligonukleotide zur behandlung des immunsuppressiven effektes des transformierenden wachstumsfaktor-beta1(tgf-beta1)
EP1762619A3 (de)	2007-05-09	Multi-tumor abweichende wachstumsgene
FI951612A0 (fi)	1995-04-05	Menetelmiä synteettisten oligonukleotidien sekvensoimiseksi, jotka sisältävät nukleotidien välisiä ei-fosfodiesterisidoksia
CA2048450A1 (en)	1992-02-24	Antisense oligonucleotide antibiotics complementary to the macromolecular synthesis operon, methods of treating bacterial infections and methods for identification of bacteria
CA2200371A1 (en)	1997-09-19	Human npik gene
NO983716D0 (no)	1998-08-13	Metoksyetoksy oligonukleotider for modulering av protein-kinase C ekspresjon
EP0702694A4 (de)	2000-10-04	$i(PSEUDOMONAS SYRINGAE) pv. $i(SYRINGAE hrpY)-GEN
WO1996038473A3 (en)	1997-04-03	Antimicrobial cationic peptides
EP1008649A3 (de)	2000-07-12	Antisense Oligonukleotide zur Behandlung von Immunosuppressive Wirkungen von TGF-beta2
CY1106978T1 (el)	2012-09-26	Ενζυμα φωσφοδιεστερασης
ZA931333B (en)	1994-08-25	Recombinant plant enzyme.
DK2256205T3 (da)	2013-07-08	Porphorymonas gingivalis-polypeptider og -polynukleotider
DE68926455D1 (de)	1996-06-13	Verfahren zur identifizierung von bakterien
ATE387493T1 (de)	2008-03-15	Gene, die für proteine mit transglykolysierungsaktivität kodieren.
PL317046A1 (en)	1997-03-03	Endotransglycosidase to tomato xyloglucane
DE69934415D1 (de)	2007-01-25	Neuartiges collectin
AU6144294A (en)	1994-09-14	Plant virus resistance conferring polyribozyme and resistant plants producing same
DE59812837D1 (de)	2005-07-07	Orotidin-5'-phosphatdecarboxylase-gen, genkonstrukt enthaltend dieses gen und seine verwendung
DE59611131D1 (de)	2004-12-09	Acarbose-Biosynthesegene aus Actinoplanes sp., Verfahren zu ihrer Isolierung sowie ihrer Verwendung
IT1255666B (it)	1995-11-09	Sequenze nucleotidiche codificanti per una dna polimerasi.
ES2109373T3 (es)	1998-01-16	Nueva proteina inhibidora de trombina a partir de garrapatas.
CA2203801A1 (en)	1996-05-09	Nucleotide sequences mediating male fertility and method of using same
TH52857A (th)	2002-09-04	แบคทีเรียของสกุล Bacillus และโปรตีนสำหรับฆ่าแมลง